With more than 50% of our early-mid stage pipeline anchored in external collaborations, we are committed to pursuing, with our partners, the healthcare solutions of the future
Boehringer Ingelheim has a proven track record of developing new treatments in its core therapeutic areas and continues to explore novel compounds with the aim of further advancing therapy for patients in areas of high unmet medical need.
From initial discovery to a marketable medicine is a long, challenging road. It takes about 12 - 15 years from discovery to the approved medication and requires an investment of about US $1 billion.
